m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG01435)
Name
Melanocortin-4 Receptor antagonist
Synonyms
Methyl 16-hydroxyhexadecanoate; AOTMRIXFFOGWDT-UHFFFAOYSA-N; 36575-67-4; Methyl juniperate; MC4 Receptor antagonist; AC1MRQ5C; SCHEMBL1245383; Methyl 16-hydroxy-hexadecanoate; CTK1B6241; DTXSID80393043; Melanocortin 4 Receptor antagonist; HS028; AKOS005066798; 16-hydroxyhexadecanoic Acid Methyl Ester; Hexadecanoic acid, 16-hydroxy-, methyl ester
    Click to Show/Hide
Status
Investigative
Structure
3D MOL
2D MOL
Formula
C17H34O3
InChI
1S/C17H34O3/c1-20-17(19)15-13-11-9-7-5-3-2-4-6-8-10-12-14-16-18/h18H,2-16H2,1H3
InChIKey
AOTMRIXFFOGWDT-UHFFFAOYSA-N
PubChem CID
3496888
TTD Drug ID
D0D1BC
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Melanocortin receptor 4 (MC4R)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Melanocortin receptor 4 (MC4R) is a therapeutic target for Melanocortin-4 Receptor antagonist. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of Melanocortin-4 Receptor antagonist through regulating the expression of Melanocortin receptor 4 (MC4R). [1], [2]
References
Ref 1 Demethyltransferase FTO alpha-ketoglutarate dependent dioxygenase (FTO) regulates the proliferation, migration, invasion and tumor growth of prostate cancer by modulating the expression of melanocortin 4 receptor (MC4R). Bioengineered. 2022 Mar;13(3):5598-5612. doi: 10.1080/21655979.2021.2001936.
Ref 2 Structure-activity relationships of novel piperazines as antagonists for the melanocortin-4 receptor. Bioorg Med Chem. 2007 Mar 1;15(5):1989-2005. doi: 10.1016/j.bmc.2006.12.039. Epub 2006 Dec 30.